One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2021-146268
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 23 |
Affiliation: Sarah Cannon, Autonomous University of Barcelona, Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris, Novartis (United States), University of Kansas Medical Center, Novartis (Switzerland), Royal Melbourne Hospital, University of Melbourne, Peter MacCallum Cancer Centre, Medical College of Wisconsin, Aix-Marseille University, Centre de Recherche en Cancérologie de Marseille, Medical University of Vienna, Vienna General Hospital, Hospital de Sant Pau
A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
